Cytosorbents Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on October 9, 2014, with a report date of October 14, 2014. The filing primarily addresses significant corporate governance changes involving the conversion of preferred stock and provides a reference to a press release regarding operational progress and preliminary revenue guidance.
Key Financial Metrics and Capital Structure Changes
The filing details a major restructuring of the company's capital structure through the conversion of all outstanding preferred stock into common stock. No specific revenue, profit, or cash flow figures are provided within the text of this 8-K; such data is referenced as being contained in a separate press release (Exhibit 99.1).
- Series A Preferred Stock: 1,894,969 shares converted into 2,583,289 shares of Common Stock.
- Series B Preferred Stock: 84,283.99 shares converted into 256,111,243 shares of Common Stock.
- Dividend Issuance: A one-time dividend of 10% was issued to Series B holders, resulting in 8,428.28 additional Series B shares prior to conversion.
- Post-Conversion Status: There are no shares of Preferred Stock issued and outstanding following these transactions.
Material Changes Versus Prior Period
The most significant material change is the elimination of the company's preferred stock classes. Key amendments included:
- Series A Conversion Price: Reduced from $1.25 per share to $0.77 per share (excluding shares covered by a 2008 agreement).
- Series B Conversion Price: Remained unchanged at $0.036 per share.
- Voting Thresholds: Amendments allowed conversion upon approval by 80% of Series A holders and a majority of Series B holders. Actual approval exceeded these thresholds (88% for Series A and 93% for Series B).
Guidance, Outlook, and Management Commentary
Management issued a press release on October 14, 2014, which is attached as Exhibit 99.1. This release contains:
- Updates on progress toward up-listing to a national exchange.
- Preliminary guidance on product revenues for the quarter ended September 30, 2014.
- Other information related to operating performance.
Note: The specific numerical values for revenue guidance and operating performance are not contained in the text of this 8-K filing.
Investor Verification Checklist
- Verify the specific preliminary revenue guidance for the quarter ended September 30, 2014, by reviewing the press release (Exhibit 99.1).
- Confirm the status of the up-listing to a national exchange mentioned in the October 14, 2014 press release.
- Review the full text of the Series A and Series B Amendments (Exhibits 3.1 and 3.2) to understand any remaining covenants or exceptions, particularly regarding the 2008 Agreement for Series A.
- Assess the impact of the significant increase in common shares outstanding (over 258 million new shares from Series B) on potential dilution.